ESC TV link:
https://www.escardio.org/Congresses-&-Events/ESC-TV/esc-tv-schedule?utm_medium=Email&utm_date=8/21/2017&utm_subscriber=003D000001SiC4fIAF&utm_campaign=ESC+-+ESC+Congress+-+18+August+2017+Non+attendees'

Advance recommendations for upcoming talks (sent by ESC) include the following three (among others)

5896 Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis:
Insights from the GLAGOV trial.
Presented by SJ Nicholls

4728 Clinical effects of anacetrapib in people with established vascular disease:
Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification
(HPS3/TIMI55-REVEAL) trial. Presented by M Landray

1151 CANTOS - The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study.
Presented by PM Ridker

On a separate but related note, Here is a link to an article entitled,
"Repairing damaged hearts with self-healing heart cells"
From the Singapore National University
https://www.eurekalert.org/pub_releases/2017-08/nuhs-rdh081817.php